Sakai Toshiyasu, Terakura Seitaro, Miyao Kotaro, Okuno Shingo, Adachi Yoshitaka, Umemura Koji, Julamanee Jakrawadee, Watanabe Keisuke, Hamana Hiroshi, Kishi Hiroyuki, Leitner Judith, Steinberger Peter, Nishida Tetsuya, Murata Makoto, Kiyoi Hitoshi
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Division of Clinical Hematology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Mol Ther Oncolytics. 2020 Aug 28;18:613-622. doi: 10.1016/j.omto.2020.08.014. eCollection 2020 Sep 25.
An artificial T cell adaptor molecule (ATAM) was generated to improve persistence of T cell receptor (TCR) gene-transduced T (TCR-T) cells compared to such persistence in a preceding study. ATAMs are gene-modified CD3ζ with the intracellular domain of 4-1BB inserted in the middle of CD3ζ. NY-ESO-1 TCR-T cells transduced with an ATAM with two separated virus vectors demonstrated superior proliferation upon antigen stimulation. To further develop clinically applicable ATAM-transduced TCR-T cells, we attempted to make a single virus vector to transduce the TCR and ATAM simultaneously. Because we failed to observe improved proliferation capacity upon stimulation after one virus vector (1vv) transduction, we compared TCR-T cells transduced with 1vv and two virus vector (2vv) methods to elucidate the reason. In Jurkat reporter cells, an ATAM transduced by the 2vv method demonstrated a higher intensity than by the 1vv method, and the ATAM intensity was associated with increased nuclear factor κB (NF-κB) signals upon stimulation. In ATAM-transduced primary T cells, a transduced ATAM by the 2vv method showed higher intensity and better proliferation. ATAM-transduced TCR-T cells demonstrated improved proliferation only when the ATAM was transduced at a higher intensity. To create a simpler transduction method, we need to develop a strategy to make a higher ATAM expression to prove the efficacy of ATAM transduction in TCR-T therapy.
为了提高T细胞受体(TCR)基因转导的T(TCR-T)细胞的持久性,我们构建了一种人工T细胞衔接分子(ATAM),并将其与之前研究中的持久性进行了比较。ATAM是经过基因修饰的CD3ζ,其细胞内结构域插入了4-1BB的中间部分。用两种分离的病毒载体转导ATAM的NY-ESO-1 TCR-T细胞在抗原刺激下表现出卓越的增殖能力。为了进一步开发临床适用的ATAM转导的TCR-T细胞,我们试图构建一种单一病毒载体来同时转导TCR和ATAM。由于在单病毒载体(1vv)转导后刺激时未观察到增殖能力的提高,我们比较了用1vv和双病毒载体(2vv)方法转导的TCR-T细胞,以阐明原因。在Jurkat报告细胞中,2vv方法转导的ATAM比1vv方法表现出更高的强度,并且刺激后ATAM强度与核因子κB(NF-κB)信号增加相关。在ATAM转导的原代T细胞中,2vv方法转导的ATAM表现出更高的强度和更好的增殖。只有当ATAM以更高强度转导时,ATAM转导的TCR-T细胞才表现出增殖改善。为了创建更简单的转导方法,我们需要开发一种策略来实现更高的ATAM表达,以证明ATAM转导在TCR-T治疗中的疗效。